Holen Sie sich die Stockscreener-App
1.19
0.83%
-0.01
Handel nachbörslich:
1.18
-0.01
-0.84%
Schlusskurs vom Vortag:
$1.20
Offen:
$1.23
24-Stunden-Volumen:
616.65K
Relative Volume:
0.80
Marktkapitalisierung:
$76.53M
Einnahmen:
$300.00K
Nettoeinkommen (Verlust:
$-27.61M
KGV:
-2.0599
EPS:
-0.5777
Netto-Cashflow:
$-22.17M
1W Leistung:
-7.03%
1M Leistung:
-19.05%
6M Leistung:
-45.41%
1J Leistung:
+49.37%
1-Tages-Spanne:
$1.15
$1.24
1-Wochen-Bereich:
$1.15
$1.3697
52-Wochen-Spanne:
$0.78
$3.82
iBio Inc Stock (IBIO) Company Profile
Firmenname
iBio Inc
Sektor
Branche
Telefon
302-355-0650
Adresse
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.19 | 76.53M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-08 | Eingeleitet | Raymond James | Outperform |
| 2026-06-05 | Eingeleitet | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-05-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-11-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-01-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Eingeleitet | Alliance Global Partners | Buy |
Alle ansehen
iBio Inc Aktie (IBIO) Neueste Nachrichten
IBIO INC (IBIO) Stock Chart - ChartMill
iBio Inc. Share PriceIBIO, RNS News, Articles, Quotes, & Charts (NASDAQ:IBIO) - proactiveinvestors.com
HC Wainwright Comments on iBio's Q1 Earnings (NASDAQ:IBIO) - MarketBeat
IBIO Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherFinancial Data - dars.gov.et
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - kalkine.com.au
HC Wainwright Upgrades iBio (NASDAQ:IBIO) to Strong-Buy - MarketBeat
H.C. Wainwright Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - Moomoo
iBio stock initiated at buy by H.C. Wainwright with $7 target - Investing.com South Africa
HC Wainwright Initiates iBio With Buy Rating, $7 Price Target - Yahoo Finance
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
IBIO Initiates Coverage On by HC Wainwright & Co. -- Price Targe - GuruFocus
IBio Price Target Announced at $7.00/Share by HC Wainwright & Co. - Moomoo
HC Wainwright & Co. initiates coverage of iBio with Buy rating, $7 price target - TradingView
Ibio, Inc. : H.c. Wainwright Initiates Covera - Moomoo
iBio Inc (0JV0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Ibio Inc For: 14 September By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
iBio updates corporate presentation, details pipeline milestones and $88M cash runway - TradingView
New iBio (NASDAQ: IBIO) investor presentation goes public - Stock Titan
iBio (NASDAQ:IBIO) Stock Rating Lowered by Wall Street Zen - MarketBeat
iBio, Inc. (IBIO) Stock Price & News - Syfe
IBIO Q2 2026 Earnings: EPS Beat Provides Minor Lift as Revenue Remains AbsentOperating Income Trends - dars.gov.et
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape By Investing.com - Investing.com South Africa
iBio at Wells Fargo healthcare conference: obesity pipeline takes shape - Investing.com
iBio (NASDAQ: IBIO) Shareholders Set to Vote on 500 Million Share Increase on October 14, 2026 - Kalkine Media
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
iBio, Inc. SEC Filing (Sep 4, 2026) - stocktitan.net
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
PharmaCyte Biotech Inc (PMCB) Peer Comparison – Compare with Others - Value Research
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - marketbeat.com
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - The Manila Times
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - moomoo.com
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio Inc. Q2 2026 Earnings: Narrower Loss Per Share Slightly Beats Estimates, Stock Slips 2.86%ROIC Trend Report - dars.gov.et
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - TradingView
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - TradingView
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - TradingView
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - TradingView
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
Finanzdaten der iBio Inc-Aktie (IBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):